Loading…
Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review
Hemophagocytic lymphohistiocytosis (HLH) is a condition characterized by a hyperinflammatory state and persistent macrophage activation, resulting in reactive phagocytosis of the hematopoietic elements. In children, it is usually a hereditary disorder, while in adults it is usually acquired secondar...
Saved in:
Published in: | Medicine (Baltimore) 2020-09, Vol.99 (39), p.e22299-e22299 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c3557-e44f4e66b6098869fef3e414dc5ca605e8e9dea560d471c990ee64df1b46b6473 |
container_end_page | e22299 |
container_issue | 39 |
container_start_page | e22299 |
container_title | Medicine (Baltimore) |
container_volume | 99 |
creator | Mendes, Fernanda Rodrigues Sobral, Karine Marques Culler, Hebert Fabricio Couto, Samuel Campanelli Freitas Pereira, Juliana Rocha, Vanderson Martinez, Gracia Aparecida Lage, Luís Alberto de Pádua Covas |
description | Hemophagocytic lymphohistiocytosis (HLH) is a condition characterized by a hyperinflammatory state and persistent macrophage activation, resulting in reactive phagocytosis of the hematopoietic elements. In children, it is usually a hereditary disorder, while in adults it is usually acquired secondary to viral infections, collagenoses, or tumors. Although accounting for 10% of hematologic malignancies, HLH is rarely associated with multiple myeloma (MM) and other plasmacytic dyscrasias.
A 64-year-old Brazilian man seeked medical care with a 3-month history of intermittent fever, weight loss, night sweats, and progressive anemic symptoms.
Total blood count showed severe bicytopenia (normocytic-normochromic anemia and thrombocytopenia), biochemical exams showed elevation of creatinine, as well as monoclonal peak in serum protein electrophoresis, high IgA dosage, and serum immunofixation with IgA kappa paraprotein. Bone marrow biopsy showed 30% of monoclonal and phenotypically anomalous plasmocytes, confirming the diagnosis of MM. Diagnosis of HLH was established by the presence of clinical and laboratory criteria: fever, splenomegaly, cytopenias, hypofibrinogenemia, hyperferritinemia, elevation of triglycerides, and several figures of erythrophagocytosis in bone marrow aspirate.
The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.
Once the diagnosis of MM and secondary hemophagocytic syndrome was established, the patient had a rapid clinical deterioration despite the established therapeutic measures, evolving with cardiovascular failure, acute liver failure, acute disseminated intravascular coagulation, worsening renal dysfunction requiring dialysis support, respiratory dysfunction, and lowering of consciousness, characterizing rapid multiple organ dysfunction, ultimately leading to the death of the patient.
Here, we aimed to describe the sixth reported case of HLH associated with MM, according to cases cataloged in the PubMed database, and the first case evaluated by 18-fluordeoxyglucose positron emission tomography (18-FDG-PETCT).
Our case report seeks to provide support for a better clinical and laboratory characterization of this rare paraneoplastic entity associated with MM, and aims to call the attention of hematologists and intensivists to this condition that falls within the scope of the differential diagnosis of r |
doi_str_mv | 10.1097/MD.0000000000022299 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32991435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3557-e44f4e66b6098869fef3e414dc5ca605e8e9dea560d471c990ee64df1b46b6473</originalsourceid><addsrcrecordid>eNpdUcluFDEQtRCIDIEvQEL-gQ52extzQBolbFKiXJKz5XFXpw3udmO7M5oD_44nA2GpS0lvK-kVQq8pOaNEq7dXF2fkz7Rtq_UTtKKCyUZoyZ-iVUVFo7TiJ-hFzl8JoUy1_Dk6YVVLORMr9GPjvi8-QYcHGOM82Lvo9sU7HPbjPMTB5-IPSMw-Y5uxn3zxNuDRTr6HXGylJxx7PC6h-DkAHvcQ4mjf4Q12NgNOMMdUsJ06HHyBZMuSDui9h91L9Ky3IcOrX_sU3X78cHP-ubm8_vTlfHPZOCaEaoDznoOUW0n0ei11Dz0DTnnnhLOSCFiD7sAKSTquqNOaAEje9XTLq4crdoreH3PnZTtC52AqyQYzJz_atDfRevMvM_nB3MV7o0TL1ozUAHYMcCnmnKB_9FJiDt8wVxfm_29U15u_zz56ftdfBfwo2MVQq8nfwrKDZAawoQwPeULptmlJS4huBWkqwhT7CWhTmfk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review</title><source>PubMed (Medline)</source><source>HEAL-Link subscriptions: Lippincott Williams & Wilkins</source><source>IngentaConnect Journals</source><creator>Mendes, Fernanda Rodrigues ; Sobral, Karine Marques ; Culler, Hebert Fabricio ; Couto, Samuel Campanelli Freitas ; Pereira, Juliana ; Rocha, Vanderson ; Martinez, Gracia Aparecida ; Lage, Luís Alberto de Pádua Covas</creator><creatorcontrib>Mendes, Fernanda Rodrigues ; Sobral, Karine Marques ; Culler, Hebert Fabricio ; Couto, Samuel Campanelli Freitas ; Pereira, Juliana ; Rocha, Vanderson ; Martinez, Gracia Aparecida ; Lage, Luís Alberto de Pádua Covas</creatorcontrib><description>Hemophagocytic lymphohistiocytosis (HLH) is a condition characterized by a hyperinflammatory state and persistent macrophage activation, resulting in reactive phagocytosis of the hematopoietic elements. In children, it is usually a hereditary disorder, while in adults it is usually acquired secondary to viral infections, collagenoses, or tumors. Although accounting for 10% of hematologic malignancies, HLH is rarely associated with multiple myeloma (MM) and other plasmacytic dyscrasias.
A 64-year-old Brazilian man seeked medical care with a 3-month history of intermittent fever, weight loss, night sweats, and progressive anemic symptoms.
Total blood count showed severe bicytopenia (normocytic-normochromic anemia and thrombocytopenia), biochemical exams showed elevation of creatinine, as well as monoclonal peak in serum protein electrophoresis, high IgA dosage, and serum immunofixation with IgA kappa paraprotein. Bone marrow biopsy showed 30% of monoclonal and phenotypically anomalous plasmocytes, confirming the diagnosis of MM. Diagnosis of HLH was established by the presence of clinical and laboratory criteria: fever, splenomegaly, cytopenias, hypofibrinogenemia, hyperferritinemia, elevation of triglycerides, and several figures of erythrophagocytosis in bone marrow aspirate.
The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.
Once the diagnosis of MM and secondary hemophagocytic syndrome was established, the patient had a rapid clinical deterioration despite the established therapeutic measures, evolving with cardiovascular failure, acute liver failure, acute disseminated intravascular coagulation, worsening renal dysfunction requiring dialysis support, respiratory dysfunction, and lowering of consciousness, characterizing rapid multiple organ dysfunction, ultimately leading to the death of the patient.
Here, we aimed to describe the sixth reported case of HLH associated with MM, according to cases cataloged in the PubMed database, and the first case evaluated by 18-fluordeoxyglucose positron emission tomography (18-FDG-PETCT).
Our case report seeks to provide support for a better clinical and laboratory characterization of this rare paraneoplastic entity associated with MM, and aims to call the attention of hematologists and intensivists to this condition that falls within the scope of the differential diagnosis of rapid onset multiple organ failure in patients with plasmacytic neoplasms.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000022299</identifier><identifier>PMID: 32991435</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Anemia - blood ; Anemia - etiology ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Agents, Alkylating - therapeutic use ; Bone Marrow - pathology ; Brazil - epidemiology ; Clinical Case Report ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; Dexamethasone - administration & dosage ; Dexamethasone - therapeutic use ; Drug Therapy, Combination ; Fatal Outcome ; Fever - diagnosis ; Fever - etiology ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Humans ; Lymphohistiocytosis, Hemophagocytic - blood ; Lymphohistiocytosis, Hemophagocytic - diagnosis ; Lymphohistiocytosis, Hemophagocytic - drug therapy ; Lymphohistiocytosis, Hemophagocytic - etiology ; Male ; Methylprednisolone - administration & dosage ; Methylprednisolone - therapeutic use ; Middle Aged ; Multiple Myeloma - complications ; Multiple Myeloma - drug therapy ; Multiple Myeloma - metabolism ; Multiple Organ Failure - complications ; Paraproteinemias - blood ; Plasma Cells - pathology ; Splenomegaly - diagnosis ; Splenomegaly - etiology ; Thrombocytopenia - blood ; Thrombocytopenia - etiology ; Weight Loss</subject><ispartof>Medicine (Baltimore), 2020-09, Vol.99 (39), p.e22299-e22299</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3557-e44f4e66b6098869fef3e414dc5ca605e8e9dea560d471c990ee64df1b46b6473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523830/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523830/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32991435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mendes, Fernanda Rodrigues</creatorcontrib><creatorcontrib>Sobral, Karine Marques</creatorcontrib><creatorcontrib>Culler, Hebert Fabricio</creatorcontrib><creatorcontrib>Couto, Samuel Campanelli Freitas</creatorcontrib><creatorcontrib>Pereira, Juliana</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>Martinez, Gracia Aparecida</creatorcontrib><creatorcontrib>Lage, Luís Alberto de Pádua Covas</creatorcontrib><title>Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Hemophagocytic lymphohistiocytosis (HLH) is a condition characterized by a hyperinflammatory state and persistent macrophage activation, resulting in reactive phagocytosis of the hematopoietic elements. In children, it is usually a hereditary disorder, while in adults it is usually acquired secondary to viral infections, collagenoses, or tumors. Although accounting for 10% of hematologic malignancies, HLH is rarely associated with multiple myeloma (MM) and other plasmacytic dyscrasias.
A 64-year-old Brazilian man seeked medical care with a 3-month history of intermittent fever, weight loss, night sweats, and progressive anemic symptoms.
Total blood count showed severe bicytopenia (normocytic-normochromic anemia and thrombocytopenia), biochemical exams showed elevation of creatinine, as well as monoclonal peak in serum protein electrophoresis, high IgA dosage, and serum immunofixation with IgA kappa paraprotein. Bone marrow biopsy showed 30% of monoclonal and phenotypically anomalous plasmocytes, confirming the diagnosis of MM. Diagnosis of HLH was established by the presence of clinical and laboratory criteria: fever, splenomegaly, cytopenias, hypofibrinogenemia, hyperferritinemia, elevation of triglycerides, and several figures of erythrophagocytosis in bone marrow aspirate.
The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.
Once the diagnosis of MM and secondary hemophagocytic syndrome was established, the patient had a rapid clinical deterioration despite the established therapeutic measures, evolving with cardiovascular failure, acute liver failure, acute disseminated intravascular coagulation, worsening renal dysfunction requiring dialysis support, respiratory dysfunction, and lowering of consciousness, characterizing rapid multiple organ dysfunction, ultimately leading to the death of the patient.
Here, we aimed to describe the sixth reported case of HLH associated with MM, according to cases cataloged in the PubMed database, and the first case evaluated by 18-fluordeoxyglucose positron emission tomography (18-FDG-PETCT).
Our case report seeks to provide support for a better clinical and laboratory characterization of this rare paraneoplastic entity associated with MM, and aims to call the attention of hematologists and intensivists to this condition that falls within the scope of the differential diagnosis of rapid onset multiple organ failure in patients with plasmacytic neoplasms.</description><subject>Anemia - blood</subject><subject>Anemia - etiology</subject><subject>Antineoplastic Agents, Alkylating - administration & dosage</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Bone Marrow - pathology</subject><subject>Brazil - epidemiology</subject><subject>Clinical Case Report</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Fatal Outcome</subject><subject>Fever - diagnosis</subject><subject>Fever - etiology</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Lymphohistiocytosis, Hemophagocytic - blood</subject><subject>Lymphohistiocytosis, Hemophagocytic - diagnosis</subject><subject>Lymphohistiocytosis, Hemophagocytic - drug therapy</subject><subject>Lymphohistiocytosis, Hemophagocytic - etiology</subject><subject>Male</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - complications</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Organ Failure - complications</subject><subject>Paraproteinemias - blood</subject><subject>Plasma Cells - pathology</subject><subject>Splenomegaly - diagnosis</subject><subject>Splenomegaly - etiology</subject><subject>Thrombocytopenia - blood</subject><subject>Thrombocytopenia - etiology</subject><subject>Weight Loss</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdUcluFDEQtRCIDIEvQEL-gQ52extzQBolbFKiXJKz5XFXpw3udmO7M5oD_44nA2GpS0lvK-kVQq8pOaNEq7dXF2fkz7Rtq_UTtKKCyUZoyZ-iVUVFo7TiJ-hFzl8JoUy1_Dk6YVVLORMr9GPjvi8-QYcHGOM82Lvo9sU7HPbjPMTB5-IPSMw-Y5uxn3zxNuDRTr6HXGylJxx7PC6h-DkAHvcQ4mjf4Q12NgNOMMdUsJ06HHyBZMuSDui9h91L9Ky3IcOrX_sU3X78cHP-ubm8_vTlfHPZOCaEaoDznoOUW0n0ei11Dz0DTnnnhLOSCFiD7sAKSTquqNOaAEje9XTLq4crdoreH3PnZTtC52AqyQYzJz_atDfRevMvM_nB3MV7o0TL1ozUAHYMcCnmnKB_9FJiDt8wVxfm_29U15u_zz56ftdfBfwo2MVQq8nfwrKDZAawoQwPeULptmlJS4huBWkqwhT7CWhTmfk</recordid><startdate>20200925</startdate><enddate>20200925</enddate><creator>Mendes, Fernanda Rodrigues</creator><creator>Sobral, Karine Marques</creator><creator>Culler, Hebert Fabricio</creator><creator>Couto, Samuel Campanelli Freitas</creator><creator>Pereira, Juliana</creator><creator>Rocha, Vanderson</creator><creator>Martinez, Gracia Aparecida</creator><creator>Lage, Luís Alberto de Pádua Covas</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200925</creationdate><title>Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review</title><author>Mendes, Fernanda Rodrigues ; Sobral, Karine Marques ; Culler, Hebert Fabricio ; Couto, Samuel Campanelli Freitas ; Pereira, Juliana ; Rocha, Vanderson ; Martinez, Gracia Aparecida ; Lage, Luís Alberto de Pádua Covas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3557-e44f4e66b6098869fef3e414dc5ca605e8e9dea560d471c990ee64df1b46b6473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anemia - blood</topic><topic>Anemia - etiology</topic><topic>Antineoplastic Agents, Alkylating - administration & dosage</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Bone Marrow - pathology</topic><topic>Brazil - epidemiology</topic><topic>Clinical Case Report</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Fatal Outcome</topic><topic>Fever - diagnosis</topic><topic>Fever - etiology</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Lymphohistiocytosis, Hemophagocytic - blood</topic><topic>Lymphohistiocytosis, Hemophagocytic - diagnosis</topic><topic>Lymphohistiocytosis, Hemophagocytic - drug therapy</topic><topic>Lymphohistiocytosis, Hemophagocytic - etiology</topic><topic>Male</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - complications</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Organ Failure - complications</topic><topic>Paraproteinemias - blood</topic><topic>Plasma Cells - pathology</topic><topic>Splenomegaly - diagnosis</topic><topic>Splenomegaly - etiology</topic><topic>Thrombocytopenia - blood</topic><topic>Thrombocytopenia - etiology</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mendes, Fernanda Rodrigues</creatorcontrib><creatorcontrib>Sobral, Karine Marques</creatorcontrib><creatorcontrib>Culler, Hebert Fabricio</creatorcontrib><creatorcontrib>Couto, Samuel Campanelli Freitas</creatorcontrib><creatorcontrib>Pereira, Juliana</creatorcontrib><creatorcontrib>Rocha, Vanderson</creatorcontrib><creatorcontrib>Martinez, Gracia Aparecida</creatorcontrib><creatorcontrib>Lage, Luís Alberto de Pádua Covas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mendes, Fernanda Rodrigues</au><au>Sobral, Karine Marques</au><au>Culler, Hebert Fabricio</au><au>Couto, Samuel Campanelli Freitas</au><au>Pereira, Juliana</au><au>Rocha, Vanderson</au><au>Martinez, Gracia Aparecida</au><au>Lage, Luís Alberto de Pádua Covas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-09-25</date><risdate>2020</risdate><volume>99</volume><issue>39</issue><spage>e22299</spage><epage>e22299</epage><pages>e22299-e22299</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Hemophagocytic lymphohistiocytosis (HLH) is a condition characterized by a hyperinflammatory state and persistent macrophage activation, resulting in reactive phagocytosis of the hematopoietic elements. In children, it is usually a hereditary disorder, while in adults it is usually acquired secondary to viral infections, collagenoses, or tumors. Although accounting for 10% of hematologic malignancies, HLH is rarely associated with multiple myeloma (MM) and other plasmacytic dyscrasias.
A 64-year-old Brazilian man seeked medical care with a 3-month history of intermittent fever, weight loss, night sweats, and progressive anemic symptoms.
Total blood count showed severe bicytopenia (normocytic-normochromic anemia and thrombocytopenia), biochemical exams showed elevation of creatinine, as well as monoclonal peak in serum protein electrophoresis, high IgA dosage, and serum immunofixation with IgA kappa paraprotein. Bone marrow biopsy showed 30% of monoclonal and phenotypically anomalous plasmocytes, confirming the diagnosis of MM. Diagnosis of HLH was established by the presence of clinical and laboratory criteria: fever, splenomegaly, cytopenias, hypofibrinogenemia, hyperferritinemia, elevation of triglycerides, and several figures of erythrophagocytosis in bone marrow aspirate.
The patient experienced pulse therapy with methylprednisolone for hemophagocytic lymphohistiocytosis, followed by initial therapy for multiple myeloma with cyclophosphamide and dexamethasone.
Once the diagnosis of MM and secondary hemophagocytic syndrome was established, the patient had a rapid clinical deterioration despite the established therapeutic measures, evolving with cardiovascular failure, acute liver failure, acute disseminated intravascular coagulation, worsening renal dysfunction requiring dialysis support, respiratory dysfunction, and lowering of consciousness, characterizing rapid multiple organ dysfunction, ultimately leading to the death of the patient.
Here, we aimed to describe the sixth reported case of HLH associated with MM, according to cases cataloged in the PubMed database, and the first case evaluated by 18-fluordeoxyglucose positron emission tomography (18-FDG-PETCT).
Our case report seeks to provide support for a better clinical and laboratory characterization of this rare paraneoplastic entity associated with MM, and aims to call the attention of hematologists and intensivists to this condition that falls within the scope of the differential diagnosis of rapid onset multiple organ failure in patients with plasmacytic neoplasms.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>32991435</pmid><doi>10.1097/MD.0000000000022299</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-7974 |
ispartof | Medicine (Baltimore), 2020-09, Vol.99 (39), p.e22299-e22299 |
issn | 0025-7974 1536-5964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523830 |
source | PubMed (Medline); HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals |
subjects | Anemia - blood Anemia - etiology Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - therapeutic use Bone Marrow - pathology Brazil - epidemiology Clinical Case Report Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Dexamethasone - administration & dosage Dexamethasone - therapeutic use Drug Therapy, Combination Fatal Outcome Fever - diagnosis Fever - etiology Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Humans Lymphohistiocytosis, Hemophagocytic - blood Lymphohistiocytosis, Hemophagocytic - diagnosis Lymphohistiocytosis, Hemophagocytic - drug therapy Lymphohistiocytosis, Hemophagocytic - etiology Male Methylprednisolone - administration & dosage Methylprednisolone - therapeutic use Middle Aged Multiple Myeloma - complications Multiple Myeloma - drug therapy Multiple Myeloma - metabolism Multiple Organ Failure - complications Paraproteinemias - blood Plasma Cells - pathology Splenomegaly - diagnosis Splenomegaly - etiology Thrombocytopenia - blood Thrombocytopenia - etiology Weight Loss |
title | Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T22%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20hemophagocytic%20lymphohistiocytosis%20as%20initial%20manifestation%20of%20multiple%20myeloma:%20A%20case%20report%20and%20literature%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Mendes,%20Fernanda%20Rodrigues&rft.date=2020-09-25&rft.volume=99&rft.issue=39&rft.spage=e22299&rft.epage=e22299&rft.pages=e22299-e22299&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000022299&rft_dat=%3Cpubmed_cross%3E32991435%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3557-e44f4e66b6098869fef3e414dc5ca605e8e9dea560d471c990ee64df1b46b6473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32991435&rfr_iscdi=true |